Table 1.
Sensitivity and specificity for STTT in America and in Europe
| Symptoms / Stage of the disease | Patient's localization | |||||
|---|---|---|---|---|---|---|
| America | Europe | |||||
| Sensitivitya | Specificityb | References | Sensitivity | Specificity | References | |
|
Erythema migrans or early Lyme borreliosis Acute phasec (AP) |
11–50% | 99% | [29, 34, 54–57] | 23–55% | 75–99% | [34, 58–61] |
|
Erythema migrans or early Lyme borreliosis Convalescent phased (CP) |
18–78% | 99% | 30–67% | 95% | [61] | |
| Acute-phase neurologic or cardiac involvement | 60–100% | 99% | 69–97% | 98–99% | [58, 61] | |
| Arthritis or late neurologic involvement | 97–100% | 99% | 78–100% | 98–99% | ||
aAbility of the test to identify the presence of a disease correctly (CDC)
bAbility of the test to identify the absence of a disease correctly (CDC)
cPhase during an active infection, characterized by active multiplication of the pathogens and pronounced symptoms
dPhase after the antibiotic treatment